Search results

(1 - 1 of 1)

Title

BAXΔ2: FROM FUNCTIONAL DOMAINS TO CANCER CORRELATION

Creator

MaÑas NÚÑez, Adriana

Date

2018, 2018-05

Description

BaxΔ2 is a functional pro-apoptotic Bax isoform, originally identified in cancer patients with microsatellite instability. Here we performed...
Show moreBaxΔ2 is a functional pro-apoptotic Bax isoform, originally identified in cancer patients with microsatellite instability. Here we performed an extensive study on BaxΔ2, covering the structure-function relationship, the clinical potential, and the human tissue expression profile. Unlike Baxa, BaxΔ2 forms aggregates and triggers non-mitochondrial cell death through caspase 8. However, the functional domain(s) responsible for BaxΔ2 unique behavior were elusive. Here we show that disruption of helix α1 makes Baxα mimic BaxΔ2, but other alterations in the N-terminus have no significant impact. We found that the core region is key for aggregation, but is not sufficient to trigger cell death. The Cterminal helical conformation, not its primary sequence, appears to be critical for caspase 8 activation. As BaxΔ2 shares core and C-terminal with most Bax isoforms, our results indicate an intrinsic potential for aggregate-mediated caspase 8-dependent cell death in other Bax family members. BaxΔ2 has been shown to sensitize cancer cells to chemotherapy, but it is a very unstable protein. Therefore, we screened a panel of proteasome inhibitors in colorectal cancer cells with different Bax statuses. We found that proteasome inhibitors can block BaxΔ2 degradation without affecting the levels of Baxa or Bcl-2. Among the inhibitors tested, bortezomib and carfilzomib were able to induce significantly higher cell death in BaxΔ2-positive cells than in cells with Baxa or no Bax. Furthermore, bortezomib-induced cell death in BaxΔ2-positive cells was predominantly dependent on the caspase 8/3 pathway. These results suggest that BaxΔ2 can selectively sensitize cancer cells to proteasome inhibitors. As many cancers have microsatellite mutations, we screened BaxΔ2 protein expression in 1090 samples of tumor and healthy tissues from several organs. We found that BaxΔ2 is expressed in 1% to 5% of cells in most organs, predominantly in healthy tissues. Production of BaxΔ2 requires a guanine deletion in the microsatellite region, but the great majority of BaxΔ2-positive tissues contained no mutation at genomic or transcript levels. Therefore, we tested Programed Ribosomal Frameshift (PRF) as a possible BaxΔ2 expression mechanism, using a double tagged construct with no mutation. We found that, though rare, PRF can lead to expression of BaxΔ2. In conclusion, BaxΔ2 can be expressed without a genetic mutation. In conclusion, BaxΔ2 is a unique isoform whose expression is the product of the extreme plasticity of the Bax gene and the biochemical circumstances in the cell. As an example of non-traditional expression, it opens the door to a whole new proteome expressed by alternative mechanisms both under physiological and pathological conditions.
Ph.D. in Biology, May 2018
Show less